Thanks to @JHepatology for giving me the opportunity to express some thought on *Precision HCC Screening" in this mini-Review, using screening post-SVR as an example
https://reader.elsevier.com/reader/sd/pii/S0168827820337302?token=FD140BB321B0949C6339F6C8D4A285BF7AED8A13240D442D846D7FDDB8EB7B20E2168CC061D3374917EF440188B20741
1/4
https://reader.elsevier.com/reader/sd/pii/S0168827820337302?token=FD140BB321B0949C6339F6C8D4A285BF7AED8A13240D442D846D7FDDB8EB7B20E2168CC061D3374917EF440188B20741
1/4
Key Concepts are:
HCC risk (incidence) is the most important determinant of cost-effectiveness of screening
Screening based on HCC risk is a superior strategy than screening based on presence absence of F3/F4 fibrosis
2/4
HCC risk (incidence) is the most important determinant of cost-effectiveness of screening
Screening based on HCC risk is a superior strategy than screening based on presence absence of F3/F4 fibrosis2/4
The Table below outlines some strategies for estimating HCC risk in individual patients.
HCC risk stratification and risk-based screening can be one of the best examples of "Precision Cancer Screening"3/4
Read on Twitter